| Ytd | -92.11% | |
| 1y | -94.44% |
| Open | 0.51 | Prev Close | 0.54 | Low | 0.39 | High | 0.52 | Mkt Cap | 5.77M |
| Vol | 90.75K | Avg Vol | 394.13K | EPS | 0.08 | P/E | 5.50 | Forward P/E | -2.02 |
| Beta | 0.47 | Short Ratio | 19.04 | Inst. Own | 30.07% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 0.57 | 200-d Avg | 4.76 | 1yr Est | 14.80 |
RVPH News
CUPERTINO, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:
CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RV
- Composition of matter provisional patent application filed for a new form of brilaroxazine designe
US stocks mixed as Dow drops over 200 points on opening. Nasdaq up 0.13%, S&P 500 down 0.13%. Te
Major M&A deals include: Amazon's $11.6 billion acquisition of Globalstar, OpenAI buys Hiro
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH - Get Free Report) has been assigned an average
- Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and saf
According to an SEC filing from Wednesday, Reviva will sell 6,666,667 common shares priced at $1.50
US stocks down, Dow falls 300+ points, S&P 500 drops 0.93%, Nasdaq falls 1.25%. Energy shares up
Five Below Inc (FIVE) shares rose 7.2% in pre-market trading after reporting better-than-expected Q4
CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:
CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:
CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:
Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH - Get Free Report) have been assigned
Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH) on Tuesday announced a regulatory update followi
Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 tria
– Pre-NDA meeting with FDA to discuss brilaroxazine's path to approval for schizophrenia planned in
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH - Get Free Report) was the recipient of a large
CUPERTINO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:
CUPERTINO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:
CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:
CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:
– Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all
CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares surged 106.3% to close at $0.21 on Wednesday afte
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 109% to $0.2115 after dipping around 48% o
Gainers FedNat Holding Company (NASDAQ: FNHC) shares climbed 107.7% to close at $0.3395 on Tuesda